The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

New cancer treatments are proving effective, but expensive, impacting overall healthcare expenditures. Researcher says reimbursements could be made conditional on reaching endpoints.

Sumitomo Mitsui Trust Group Inc. lowered its stake in Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...